Pfizer announced on March 3 to have entered multiple agreements with Aurobindo Pharma Ltd, a generic drug company based in India, to produce and sell drugs that have lost patent protection in the US and Europe. Under the contract, Pfizer has acquired the right to sell 39 pills that will be sold in the US, of which 20 also in Europe, and 12 injectable medicines such as antibiotics. Pfizer will be responsible for the marketing after licensing each product and Aurobindo will handle all the steps to get approval to make generic versions, as well as manufacturing them.